Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation

xlomafota13 shared this article with you from Inoreader Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation Via American Journal of Blood Research Am J Blood Res. 2020 Dec 15;10(6):339-344. eCollection 2020. ABSTRACT BACKGROUND: Infections are major contributor to morbidity and mortality in patients undergoing bone marrow transplant (BMT). OBJECTIVE: To assess role of serum procalcitonin (PCT) as a useful biomarker for the infections and outcomes in these patients. METHODS: Retrospective observational study. RESULTS: Total 47 patients with febrile episodes were enrolled. Twenty patients underwent autologous BMT and 27 underwent allogeneic BMT. Bacterial infections were documented in 18/47 (38%) patients. Forty patients were neutropenic. The median fever duration was 10 days (range 3-30 days) in positive procalcitonin level group whereas it was 4 days (range 1-18) in negative group. This was statistically significant (P=0.000). Procalcitonin levels were high in 8/9 episodes of sepsis (P=0.029). Intensive care unit transfers and death were significantly higher in PCT positive group as compared to PCT negative group. CONCLUSION: Serum procalcitonin levels provide prognostic information of worse outcome in patients undergoing HSCT. PMID:33489442 | PMC:PMC7811896 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.